SPG11 Cytoskeletal Protein

SPG11 Cytoskeletal Protein

Overview

SPG11 Cytoskeletal Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">SPG11 Cytoskeletal Protein</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SPG11</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q21.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>80208</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q96MC7</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,133 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~300 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Predominantly neuronal</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal Recessive</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">Neurodegeneration</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">13 edges</a></td>
</tr>
</table>

SPG11 (also known as spatacsin) is a large cytoplasmic protein encoded by the SPG11 gene located on chromosome 15q21.1. It is predominantly expressed in the nervous system, particularly in [neurons](/entities/neurons), and plays a critical role in cellular homeostasis, [autophagy](/entities/autophagy), and cytoskeletal organization. Mutations in the SPG11 gene are the most common cause of autosomal recessive hereditary spastic paraplegia (HSP), accounting for approximately 20-30% of recessive HSP cases [1][2]. [@berciano2015]

The protein is characterized by its large molecular weight (~300 kDa) and contains multiple conserved domains including a WD40 repeat domain and a VERLIN (VPS13, ERGIC, & TIRAP-Like) domain, which are implicated in protein-protein interactions and membrane trafficking [3]. [@marti2019]

Structure and Molecular Biology

Protein Domains

SPG11 consists of 2,133 amino acids and contains several functionally important domains: [@guzmansoto2021]

Expression Pattern

In the human brain, SPG11 is highly expressed in: [@repeat2020]

• Cerebral [cortex](/brain-regions/cortex) (layer V pyramidal neurons)
• [Hippocampus](/brain-regions/hippocampus) (CA1-CA3 regions)
• Basal ganglia
• Cerebellar Purkinje cells
• Spinal cord motor neurons

Cellular Functions

Autophagy Regulation

SPG11 plays a fundamental role in autophagy, the cellular process of degrading and recycling damaged organelles and protein aggregates. It interacts with key autophagy proteins including: [@spg2018]

• ATG5-ATG12 complex: SPG11 facilitates the conjugation of ATG5 to ATG12, a critical step in autophagosome formation [6].
• LC3 (MAP1LC3): SPG11 colocalizes with LC3-positive autophagosomes and regulates lipidation of LC3.
• mTORC1 signaling: SPG11 modulates mTORC1 activity, a central regulator of autophagy initiation.

Cytoskeletal Organization

SPG11 associates with microtubules and actin filaments, contributing to: [@axonal2020]

• Axonal transport: SPG11 regulates the trafficking of organelles and signaling complexes along axons via microtubule-based motors [8].
• Neuronal polarity: Essential for establishing and maintaining axonal and dendritic compartments.
• Synaptic function: Involved in presynaptic vesicle dynamics and postsynaptic density organization.

Endolysosomal Trafficking

SPG11 participates in endolysosomal pathway regulation: [@clinical2021]

• Controls trafficking from early endosomes to late endosomes/lysosomes
• Regulates lysosomal biogenesis and function
• Impacts neurotrophin receptor (TrkB) trafficking and signaling

Role in Neurodegenerative Diseases

Hereditary Spastic Paraplegia Type 15 (SPG15)

SPG11 is the primary cause of SPG15, characterized by: [@spg2022]

Clinical Features: [@autophagy2021]

• Progressive lower limb spasticity and weakness (spastic paraplegia)
• Thin corpus callosum (observed on MRI)
• Cognitive impairment (ranging from mild to severe)
• Peripheral neuropathy
• Seizures in some cases
• Early-onset (typically in childhood or adolescence) [9]

• Degeneration of corticospinal tracts
• Loss of neurons in the motor cortex
• Abnormal storage material in fibroblasts
• Accumulation of autofluorescent lipopigments

Relationship to Other Neurodegenerative Diseases

While primarily associated with HSP, SPG11 dysfunction may contribute to: [@gene2023]

Alzheimer's Disease (AD): [@spg2017]

• Autophagy impairment is a hallmark of AD
• SPG11 mutations may exacerbate [amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology
• Some studies suggest SPG11 variants modify AD risk [10]

• Autophagy-lysosomal pathway dysfunction is implicated in PD
• SPG11 deficiency may affect [alpha-synuclein](/proteins/alpha-synuclein) clearance
• Possible overlap with PD pathogenesis [11]

• Similarities in corticospinal tract degeneration
• Autophagy defects observed in ALS models
• SPG11 variants may modify disease progression [12]

Genetic Information

Known Pathogenic Variants

Over 150 pathogenic variants have been identified in SPG11, including:

• Nonsense mutations (premature stop codons)
• Frameshift insertions/deletions
• Splice site mutations
• Large genomic deletions

Therapeutic Implications

Current Understanding

No disease-modifying therapies exist for SPG11-related disorders. Current management includes:

• Physical therapy for spasticity
• Antispastic medications (baclofen, tizanidine)
• Assistive devices for mobility
• Supportive care for cognitive symptoms

Therapeutic Targets

Potential therapeutic strategies include:

Research Methods

Experimental Models

• Knockout mouse models: Spg11−/− mice recapitulate key features of human disease [14]
• Zebrafish models: Morpholino knockdowns demonstrate motor axon defects
• Patient-derived iPSCs: Neurons from SPG11 patients show autophagy defects

Biomarkers

• Elevated [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) in cerebrospinal fluid (potential progression marker)
• MRI findings: thin corpus callosum, white matter abnormalities
• Skin biopsy: characteristic cytoplasmic inclusions

Summary

SPG11 (spatacsin) is a critical neuronal protein involved in autophagy, cytoskeletal organization, and endolysosomal trafficking. Loss-of-function mutations cause hereditary spastic paraplegia type 15 (SPG15), the most common form of autosomal recessive HSP. The protein's role in autophagy places it at the intersection of multiple neurodegenerative processes, and understanding SPG11 function may provide insights into broader neurodegenerative mechanisms affecting Alzheimer's disease, Parkinson's disease, and ALS. Future therapeutic approaches focusing on gene replacement and autophagy modulation hold promise for treating this devastating disorder.

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SPG11 Cytoskeletal Protein discovered through SciDEX knowledge graph analysis: